The European Medicines Agency's CHMP has recommended marketing authorization for Novo Nordisk's Wegovy 7.2 mg single-dose pen for obesity treatment in the EU. Clinical trials showed an average weight loss of 20.7% in obese patients, with about one-third achieving 25% or more weight loss. This new single-dose pen offers a more convenient option compared to the current multi-injection regimen. Novo Nordisk plans to launch this product in the EU in Q3 2026, expanding treatment options for obesity.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
